• Mike Briley
  • David Nutt

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages I-IX
  2. Caroline McGrath, Graham D. Burrows, Trevor R. Norman
    Pages 1-11
  3. Darius K. Shayegan, Stephen M. Stahl
    Pages 13-25
  4. Rudolf Hoehn-Saric
    Pages 27-39
  5. Guy Griebel, Ghislaine Perrault, David J. Sanger
    Pages 77-94
  6. Louise R. Levine, William Z. Potter
    Pages 95-104
  7. Chantal Moret
    Pages 105-118
  8. François Jenck, Jean-Luc Moreau, Jürgen Wichmann, Heinz Stadler, James R. Martin, Michael Bös
    Pages 119-137
  9. Phil Skolnick
    Pages 139-150
  10. Spilios V. Argyropoulos, David J. Nutt
    Pages 151-175
  11. Back Matter
    Pages 177-181

About this book


For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi­ azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.


brain development drug drugs feeling future peptides pharmaceutical pharmacology research serotonin

Editors and affiliations

  • Mike Briley
    • 1
  • David Nutt
    • 2
  1. 1.Institut de Recherche Pierre FabreParc Industriel de la ChartreuseCastresFrance
  2. 2.Psychopharmacology Unit School of Medical ScienceUniversity of BristolBristolUK

Bibliographic information

Industry Sectors
Health & Hospitals